{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:08:28Z","timestamp":1789924108629,"version":"4.0.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Society for the Promotion of Research in Experimental Neurology, Vienna, Austria"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00702-024-02750-w","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T16:21:18Z","timestamp":1707841278000},"page":"1511-1522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The pathobiology of depression in Huntington\u2019s disease: an unresolved puzzle"],"prefix":"10.1007","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9641-7649","authenticated-orcid":false,"given":"Kurt A.","family":"Jellinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"2750_CR1","doi-asserted-by":"publisher","first-page":"e230389","DOI":"10.1136\/bcr-2019-230389","volume":"12","author":"H Abeysundera","year":"2019","unstructured":"Abeysundera H, Campbell A, Sarma S (2019) Worsening of movement disorder following treatment with electroconvulsive therapy in a patient with Huntington\u2019s disease. BMJ Case Rep 12:e230389","journal-title":"BMJ Case Rep"},{"key":"2750_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JHD-190361","volume":"8","author":"J Adrissi","year":"2019","unstructured":"Adrissi J, Nadkarni NA, Gausche E, Bega D (2019) Electroconvulsive therapy (ECT) for refractory psychiatric symptoms in Huntington\u2019s disease: a case series and review of the literature. J Huntingtons Dis 8:291\u2013300","journal-title":"J Huntingtons Dis"},{"key":"2750_CR3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington, VA","edition":"5"},{"key":"2750_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JHD-160206","volume":"5","author":"KE Anderson","year":"2016","unstructured":"Anderson KE, Eberly S, Groves M, Kayson E, Marder K, Young AB, Shoulson I (2016) Risk factors for suicidal ideation in people at risk for Huntington\u2019s disease. J Huntingtons Dis 5:389\u2013394","journal-title":"J Huntingtons Dis"},{"key":"2750_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/mds.25750","volume":"29","author":"LJ Beglinger","year":"2014","unstructured":"Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS (2014) Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord 29:401\u2013405","journal-title":"Mov Disord"},{"key":"2750_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JHD-220537","volume":"11","author":"H Bilal","year":"2022","unstructured":"Bilal H, Warren N, Dahanayake P, Kelso W, Farrand S, Stout JC (2022) The lived experiences of depression in Huntington\u2019s disease: a qualitative study. J Huntingtons Dis 11:321\u2013335","journal-title":"J Huntingtons Dis"},{"key":"2750_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jad.2023.02.035","volume":"328","author":"H Bilal","year":"2023","unstructured":"Bilal H, Harding IH, Stout JC (2023) The temporal dynamics of mood and their association with depressive symptoms in Huntington\u2019s disease. J Affect Disord 328:22\u201328","journal-title":"J Affect Disord"},{"key":"2750_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00415-023-11982-x","volume":"271","author":"H Bilal","year":"2024","unstructured":"Bilal H, Harding IH, Stout JC (2024) The relationship between disease-specific psychosocial stressors and depressive symptoms in Huntington\u2019s disease. J Neurol 271:289\u2013299","journal-title":"J Neurol"},{"key":"2750_CR9","first-page":"77","volume":"28","author":"A Butenaite","year":"2021","unstructured":"Butenaite A, Strumila R, Lengvenyte A, Pakutkaite IK, Morkuniene A, Matuleviciene A, Dlugauskas E, Utkus A (2021) Significant association between huntingtin gene mutation and prevalence of hopelessness, depression and anxiety symptoms. Acta Med Litu 28:77\u201385","journal-title":"Acta Med Litu"},{"key":"2750_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/jcm12010206","volume":"12","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Gu X, Liu K, Yang T, Xiao Y, Jiang Q, Huang J, Lin J, Wei Q, Ou R, Hou Y, Zhang L, Li C, Burgunder JM, Shang H (2022) The comprehensive analysis of motor and neuropsychiatric symptoms in patients with Huntington\u2019s disease from china: a cross-sectional study. J Clin Med 12:206","journal-title":"J Clin Med"},{"key":"2750_CR11","unstructured":"Chu A, Wadhwa R (2023) Selective serotonin reuptake inhibitors. In: StatPearls [Internet], 2023\/05\/01 Edition. StatPearls Publishing. www.ncbi.nlm.nih.gov\/books\/NBK554406 Treasure Island (FL)"},{"key":"2750_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbr.2015.05.010","volume":"291","author":"A Ciamei","year":"2015","unstructured":"Ciamei A, Detloff PJ, Morton AJ (2015) Progression of behavioural despair in R6\/2 and Hdh knock-in mouse models recapitulates depression in Huntington\u2019s disease. Behav Brain Res 291:140\u2013146","journal-title":"Behav Brain Res"},{"key":"2750_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1037\/neu0000793","volume":"36","author":"AE Ciriegio","year":"2022","unstructured":"Ciriegio AE, Watson KH, Pfalzer AC, Hale L, Huitz E, Moroz S, Roth MC, Snow ALB, Jones MT, Guthrie CS, Brown B, Grice V, McDonell KE, Claassen DO, Compas BE (2022) Inhibitory control, working memory and coping with stress: associations with symptoms of anxiety and depression in adults with Huntington\u2019s disease. Neuropsychology 36:288\u2013296","journal-title":"Neuropsychology"},{"key":"2750_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105166","volume":"149","author":"ML Clark","year":"2023","unstructured":"Clark ML, Abimanyi-Ochom J, Le H, Long B, Orr C, Le Khanh-Dao L (2023) A systematic review and meta-analysis of depression and apathy frequency in adult-onset Huntington\u2019s disease. Neurosci Biobehav Rev 149:105166","journal-title":"Neurosci Biobehav Rev"},{"key":"2750_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1089\/gte.2004.8.114","volume":"8","author":"AM Codori","year":"2004","unstructured":"Codori AM, Slavney PR, Rosenblatt A, Brandt J (2004) Prevalence of major depression one year after predictive testing for Huntington\u2019s disease. Genet Test 8:114\u2013119","journal-title":"Genet Test"},{"key":"2750_CR16","doi-asserted-by":"publisher","first-page":"8474","DOI":"10.3390\/ijms21228474","volume":"21","author":"GD Colpo","year":"2020","unstructured":"Colpo GD, Rocha NP, Furr Stimming E, Teixeira AL (2020) Gene expression profiling in Huntington\u2019s disease: does comorbidity with depressive symptoms matter? Int J Mol Sci 21:8474","journal-title":"Int J Mol Sci"},{"key":"2750_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1176\/appi.neuropsych.21070191","volume":"35","author":"MH Connors","year":"2023","unstructured":"Connors MH, Teixeira-Pinto A, Loy CT (2023) Apathy and depression in Huntington\u2019s disease: distinct longitudinal trajectories and clinical correlates. J Neuropsychiatry Clin Neurosci 35:69\u201376","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"678","key":"2750_CR18","first-page":"e673","volume":"35","author":"C Cusin","year":"2013","unstructured":"Cusin C, Franco FB, Fernandez-Robles C, DuBois CM, Welch CA (2013) Rapid improvement of depression and psychotic symptoms in Huntington\u2019s disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. Gen Hosp Psychiatry 35(678):e673-675","journal-title":"Gen Hosp Psychiatry"},{"key":"2750_CR19","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1007\/s12035-018-0890-6","volume":"55","author":"VS da Fons\u00eaca","year":"2018","unstructured":"da Fons\u00eaca VS, da Silva Colla AR, de Paula N-C, Pl\u00e1cido E, Rosa JM, Farina M, Gil-Mohapel J, Rodrigues ALS, Brocardo PS (2018) Brain-derived neurotrophic factor prevents depressive-like behaviors in early-symptomatic YAC128 Huntington\u2019s disease mice. Mol Neurobiol 55:7201\u20137215","journal-title":"Mol Neurobiol"},{"key":"2750_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jpsychores.2015.11.003","volume":"80","author":"M Dale","year":"2016","unstructured":"Dale M, Maltby J, Shimozaki S, Cramp R, Rickards H (2016) Disease stage, but not sex, predicts depression and psychological distress in Huntington\u2019s disease: a European population study. J Psychosom Res 80:17\u201322","journal-title":"J Psychosom Res"},{"key":"2750_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/mds.22837","volume":"25","author":"J De Souza","year":"2010","unstructured":"De Souza J, Jones LA, Rickards H (2010) Validation of self-report depression rating scales in Huntington\u2019s disease. Mov Disord 25:91\u201396","journal-title":"Mov Disord"},{"key":"2750_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JHD-130071","volume":"2","author":"ER Dorsey","year":"2013","unstructured":"Dorsey ER, Brocht AF, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, Biglan KM, Shoulson I (2013) Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis 2:509\u2013515","journal-title":"J Huntingtons Dis"},{"key":"2750_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fneur.2013.00081","volume":"4","author":"X Du","year":"2013","unstructured":"Du X, Pang TY, Hannan AJ (2013) A tale of two maladies? Pathogenesis of depression with and without the Huntington\u2019s disease gene mutation. Front Neurol 4:81","journal-title":"Front Neurol"},{"key":"2750_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2741\/S355","volume":"5","author":"EM Dumas","year":"2013","unstructured":"Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA (2013) A review of cognition in Huntington\u2019s disease. Front Biosci (schol Ed) 5:1\u201318","journal-title":"Front Biosci (schol Ed)"},{"key":"2750_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1017\/CBO9781107588660.011","volume-title":"Neuropathology of neurodegenerative diseases: a practical guide","author":"C Duyckaerts","year":"2014","unstructured":"Duyckaerts C, Joyon N, D\u00fcrr A (2014) Neurodegenerative diseases linked to trinucleotide repeats. In: Kovacs G (ed) Neuropathology of neurodegenerative diseases: a practical guide. Cambridge University Press, Cambridge, pp 195\u2013208"},{"key":"2750_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.biopsych.2019.12.010","volume":"87","author":"N Ellis","year":"2020","unstructured":"Ellis N, Tee A, McAllister B, Massey T, McLauchlan D, Stone T, Correia K, Loupe J, Kim KH, Barker D, Hong EP, Chao MJ, Long JD, Lucente D, Vonsattel JPG, Pinto RM, Elneel KA, Ramos EM, Mysore JS, Gillis T, Wheeler VC, Medway C, Hall L, Kwak S, Sampaio C, Ciosi M, Maxwell A, Chatzi A, Monckton DG, Orth M, Landwehrmeyer GB, Paulsen JS, Shoulson I, Myers RH, van Duijn E, Rickards H, MacDonald ME, Lee JM, Gusella JF, Jones L, Holmans P (2020) Genetic risk underlying psychiatric and cognitive symptoms in Huntington\u2019s disease. Biol Psychiatry 87:857\u2013865","journal-title":"Biol Psychiatry"},{"key":"2750_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1089\/jpm.2021.0308","volume":"25","author":"M El-Sourady","year":"2022","unstructured":"El-Sourady M, Martin S, Wong HN, Carroll T (2022) A scoping review of palliative care for adults with Huntington\u2019s disease: current practice and future directions. J Palliat Med 25:488\u2013505","journal-title":"J Palliat Med"},{"key":"2750_CR28","doi-asserted-by":"publisher","first-page":"117957352210925","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2022) Current and possible future therapeutic options for Huntington\u2019s disease. J Cent Nerv Syst Dis 14:11795735221092516","journal-title":"J Cent Nerv Syst Dis"},{"key":"2750_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28855","volume":"37","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Rodrigues FB, Duarte GS, Mestre TA, Bachoud-Levi AC, Bentivoglio AR, Burgunder JM, Cardoso F, Claassen DO, Landwehrmeyer GB, Kulisevsky J, Nirenberg MJ, Rosser A, Roth J, Seppi K, Slawek J, Furr-Stimming E, Tabrizi SJ, Walker FO, Vandenberghe W, Costa J, Sampaio C (2022) An MDS evidence-based review on treatments for Huntington\u2019s disease. Mov Disord 37:25\u201335","journal-title":"Mov Disord"},{"key":"2750_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000327754","volume":"8","author":"JG Fiedorowicz","year":"2011","unstructured":"Fiedorowicz JG, Mills JA, Ruggle A, Langbehn D, Paulsen JS (2011) Suicidal behavior in prodromal Huntington disease. Neurodegener Dis 8:483\u2013490","journal-title":"Neurodegener Dis"},{"key":"2750_CR31","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","volume":"36","author":"S Frank","year":"2022","unstructured":"Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O\u2019Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM (2022) The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study. CNS Drugs 36:1207\u20131216","journal-title":"CNS Drugs"},{"key":"2750_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neubiorev.2019.04.002","volume":"102","author":"CPC Galts","year":"2019","unstructured":"Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker JS, Gil-Mohapel J (2019) Depression in neurodegenerative diseases: common mechanisms and current treatment options. Neurosci Biobehav Rev 102:56\u201384","journal-title":"Neurosci Biobehav Rev"},{"key":"2750_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/jpm13030385","volume":"13","author":"X Garc\u00eda-Gonz\u00e1lez","year":"2023","unstructured":"Garc\u00eda-Gonz\u00e1lez X, Cubo E, Sim\u00f3n-Vicente L, Mariscal N, Alcaraz R, Aguado L, Rivadeneyra-Posadas J, Sanz-Solas A, Saiz-Rodr\u00edguez M (2023) Pharmacogenetics in the treatment of Huntington\u2019s disease: review and future perspectives. J Pers Med 13:385","journal-title":"J Pers Med"},{"key":"2750_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101900","volume":"23","author":"C Garcia-Gorro","year":"2019","unstructured":"Garcia-Gorro C, Llera A, Martinez-Horta S, Perez-Perez J, Kulisevsky J, Rodriguez-Dechicha N, Vaquer I, Subira S, Calopa M, Mu\u00f1oz E, Santacruz P, Ruiz-Idiago J, Mareca C, Beckmann CF, de Diego-Balaguer R, Camara E (2019) Specific patterns of brain alterations underlie distinct clinical profiles in Huntington\u2019s disease. Neuroimage Clin 23:101900","journal-title":"Neuroimage Clin"},{"key":"2750_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.116","volume":"7","author":"SL Gardiner","year":"2017","unstructured":"Gardiner SL, van Belzen MJ, Boogaard MW, van Roon-Mom WMC, Rozing MP, van Hemert AM, Smit JH, Beekman ATF, van Grootheest G, Schoevers RA, Oude Voshaar RC, Comijs HC, Penninx B, van der Mast RC, Roos RAC, Aziz NA (2017a) Large normal-range TBP and ATXN7 CAG repeat lengths are associated with increased lifetime risk of depression. Transl Psychiatry 7:e1143","journal-title":"Transl Psychiatry"},{"key":"2750_CR36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41398-017-0042-1","volume":"7","author":"SL Gardiner","year":"2017","unstructured":"Gardiner SL, van Belzen MJ, Boogaard MW, van Roon-Mom WMC, Rozing MP, van Hemert AM, Smit JH, Beekman ATF, van Grootheest G, Schoevers RA, Oude Voshaar RC, Roos RAC, Comijs HC, Penninx B, van der Mast RC, Aziz NA (2017b) Huntingtin gene repeat size variations affect risk of lifetime depression. Transl Psychiatry 7:1277","journal-title":"Transl Psychiatry"},{"key":"2750_CR37","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1177\/0269881198012003021","volume":"12","author":"PJ Goodnick","year":"1998","unstructured":"Goodnick PJ, Goldstein BJ (1998) Selective serotonin reuptake inhibitors in affective disorders \u2013 I. Basic pharmacology. J Psychopharmacol 12:S5-20","journal-title":"J Psychopharmacol"},{"key":"2750_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3233\/JHD-150160","volume":"4","author":"S Gregory","year":"2015","unstructured":"Gregory S, Scahill RI, Seunarine KK, Stopford C, Zhang H, Zhang J, Orth M, Durr A, Roos RA, Langbehn DR, Long JD, Johnson H, Rees G, Tabrizi SJ, Craufurd D (2015) Neuropsychiatry and white matter microstructure in Huntington\u2019s disease. J Huntingtons Dis 4:239\u2013249","journal-title":"J Huntingtons Dis"},{"key":"2750_CR39","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","volume":"22","author":"HE Grote","year":"2005","unstructured":"Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, Hannan AJ (2005) Cognitive disorders and neurogenesis deficits in Huntington\u2019s disease mice are rescued by fluoxetine. Eur J Neurosci 22:2081\u20132088","journal-title":"Eur J Neurosci"},{"key":"2750_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104958","volume":"142","author":"C Gubert","year":"2020","unstructured":"Gubert C, Renoir T, Hannan AJ (2020) Why Woody got the blues: the neurobiology of depression in Huntington\u2019s disease. Neurobiol Dis 142:104958","journal-title":"Neurobiol Dis"},{"key":"2750_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/arclin\/4.1.79","volume":"4","author":"S Hall","year":"1989","unstructured":"Hall S, Bigler ED, Rutledge JN (1989) Depression preceding choreiform movements in Huntington\u2019s disease: a case study. Arch Clin Neuropsychol 4:79\u201392","journal-title":"Arch Clin Neuropsychol"},{"key":"2750_CR42","doi-asserted-by":"publisher","first-page":"fcac294","DOI":"10.1093\/braincomms\/fcac294","volume":"4","author":"AJ Hannan","year":"2022","unstructured":"Hannan AJ (2022) Chorea me a river: depression in Huntington\u2019s disease as an exemplar of precision medicine. Brain Commun 4:fcac294","journal-title":"Brain Commun"},{"key":"2750_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cortex.2019.07.014","volume":"119","author":"KL Harris","year":"2019","unstructured":"Harris KL, Armstrong M, Swain R, Erzinclioglu S, Das T, Burgess N, Barker RA, Mason SL (2019) Huntington\u2019s disease patients display progressive deficits in hippocampal-dependent cognition during a task of spatial memory. Cortex 119:417\u2013427","journal-title":"Cortex"},{"key":"2750_CR44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3233\/JHD-180318","volume":"8","author":"Y He","year":"2019","unstructured":"He Y, Suofu Y, Yablonska S, Wang X, Larkin TM, Kim J, Carlisle DL, Friedlander RM (2019) Increased serotonin transporter expression in Huntington\u2019s disease patients is not consistently replicated in murine models. J Huntingtons Dis 8:449\u2013457","journal-title":"J Huntingtons Dis"},{"key":"2750_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","volume":"25","author":"AK Holl","year":"2010","unstructured":"Holl AK, Wilkinson L, Painold A, Holl EM, Bonelli RM (2010) Combating depression in Huntington\u2019s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 25:46\u201350","journal-title":"Int Clin Psychopharmacol"},{"key":"2750_CR46","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1007\/s00415-018-9013-6","volume":"265","author":"P Honrath","year":"2018","unstructured":"Honrath P, Dogan I, Wudarczyk O, G\u00f6rlich KS, Votinov M, Werner CJ, Schumann B, Overbeck RT, Schulz JB, Landwehrmeyer BG, Gur RE, Habel U, Reetz K (2018) Risk factors of suicidal ideation in Huntington\u2019s disease: literature review and data from Enroll-HD. J Neurol 265:2548\u20132561","journal-title":"J Neurol"},{"key":"2750_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jad.2011.10.031","volume":"136","author":"AA Hubers","year":"2012","unstructured":"Hubers AA, Reedeker N, Giltay EJ, Roos RA, van Duijn E, van der Mast RC (2012) Suicidality in Huntington\u2019s disease. J Affect Disord 136:550\u2013557","journal-title":"J Affect Disord"},{"key":"2750_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jad.2013.06.001","volume":"151","author":"AA Hubers","year":"2013","unstructured":"Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Landwehrmeyer BG, van der Mast RC, Giltay EJ (2013) Suicidal ideation in a European Huntington\u2019s disease population. J Affect Disord 151:248\u2013258","journal-title":"J Affect Disord"},{"key":"2750_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/jne.12255","volume":"27","author":"AA Hubers","year":"2015","unstructured":"Hubers AA, van der Mast RC, Pereira AM, Roos RA, Veen LJ, Cobbaert CM, van Duijn E, Giltay EJ (2015) Hypothalamic-pituitary-adrenal axis functioning in Huntington\u2019s disease and its association with depressive symptoms and suicidality. J Neuroendocrinol 27:234\u2013244","journal-title":"J Neuroendocrinol"},{"key":"2750_CR50","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1093\/hmg\/ddt203","volume":"22","author":"S Hult Lundh","year":"2013","unstructured":"Hult Lundh S, Nilsson N, Soylu R, Kirik D, Peters\u00e9n \u00c5 (2013) Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet 22:3485\u20133497","journal-title":"Hum Mol Genet"},{"key":"2750_CR51","unstructured":"Huntington G (1872) On chorea. Med Surg Reporter 26:317-321. https:\/\/neuro.psychiatryonline.org\/doi\/pdf\/310.1176\/jnp.1115.1171.1109."},{"key":"2750_CR52","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Huntington's Disease Collaborative Research Group","year":"1993","unstructured":"Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 72:971\u2013983","journal-title":"Cell"},{"issue":"Suppl 1","key":"2750_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00004850-199403001-00004","volume":"9","author":"J Hyttel","year":"1994","unstructured":"Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9(Suppl 1):19\u201326","journal-title":"Int Clin Psychopharmacol"},{"key":"2750_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejphar.2015.10.033","volume":"769","author":"S Jamwal","year":"2015","unstructured":"Jamwal S, Kumar P (2015) Antidepressants for neuroprotection in Huntington\u2019s disease: a review. Eur J Pharmacol 769:33\u201342","journal-title":"Eur J Pharmacol"},{"key":"2750_CR55","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00702-022-02559-5","volume":"129","author":"KA Jellinger","year":"2022","unstructured":"Jellinger KA (2022) The pathobiological basis of depression in Parkinson disease: challenges and outlooks. J Neural Transm (vienna) 129:1397\u20131418","journal-title":"J Neural Transm (vienna)"},{"key":"2750_CR56","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00702-023-02669-8","volume":"130","author":"KA Jellinger","year":"2023","unstructured":"Jellinger KA (2023) Depression in dementia with Lewy bodies: a critical update. J Neural Transm (vienna) 130:1207\u20131218","journal-title":"J Neural Transm (vienna)"},{"key":"2750_CR57","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jad.2019.03.043","volume":"250","author":"ZR Kachian","year":"2019","unstructured":"Kachian ZR, Cohen-Zimerman S, Bega D, Gordon B, Grafman J (2019) Suicidal ideation and behavior in Huntington\u2019s disease: systematic review and recommendations. J Affect Disord 250:319\u2013329","journal-title":"J Affect Disord"},{"key":"2750_CR58","doi-asserted-by":"publisher","first-page":"437","DOI":"10.15406\/jabb.12017.15403.00082","volume":"3","author":"SB Khushboo","year":"2017","unstructured":"Khushboo SB (2017) Antidepressants: mechanism of action, toxicity and possible amelioration. J Appl Biotechnol Bioeng 3:437\u2013448. https:\/\/doi.org\/10.15406\/jabb.12017.15403.00082","journal-title":"J Appl Biotechnol Bioeng"},{"key":"2750_CR59","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/JHD-170280","volume":"7","author":"J Kobal","year":"2018","unstructured":"Kobal J, Matej K, Ko\u017eelj M, Podnar S (2018) Anorectal dysfunction in presymptomatic mutation carriers and patients with Huntington\u2019s disease. J Huntingtons Dis 7:259\u2013267","journal-title":"J Huntingtons Dis"},{"key":"2750_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1503\/jpn.100067","volume":"36","author":"C Krogias","year":"2011","unstructured":"Krogias C, Strassburger K, Eyding J, Gold R, Norra C, Juckel G, Saft C, Ninphius D (2011) Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. J Psychiatry Neurosci 36:187\u2013194","journal-title":"J Psychiatry Neurosci"},{"key":"2750_CR61","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.2174\/1389203718666170710121532","volume":"18","author":"E Kulikova","year":"2017","unstructured":"Kulikova E, Kulikov A (2017) Striatal-enriched tyrosine protein phosphatase (STEP) in the mechanisms of depressive disorders. Curr Protein Pept Sci 18:1152\u20131162","journal-title":"Curr Protein Pept Sci"},{"key":"2750_CR62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","volume":"25","author":"S Martinez-Horta","year":"2016","unstructured":"Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB, Kulisevsky J (2016) Neuropsychiatric symptoms are very common in premanifest and early stage Huntington\u2019s disease. Parkinsonism Relat Disord 25:58\u201364","journal-title":"Parkinsonism Relat Disord"},{"key":"2750_CR63","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1002\/hbm.23527","volume":"38","author":"P McColgan","year":"2017","unstructured":"McColgan P, Razi A, Gregory S, Seunarine KK, Durr A, Raymund ACR, Leavitt BR, Scahill RI, Clark CA, Langbehn DR, Rees G, Tabrizi SJ (2017) Structural and functional brain network correlates of depressive symptoms in premanifest Huntington\u2019s disease. Hum Brain Mapp 38:2819\u20132829","journal-title":"Hum Brain Mapp"},{"key":"2750_CR64","doi-asserted-by":"publisher","first-page":"e1643","DOI":"10.1212\/WNL.0000000000007244","volume":"92","author":"A McGarry","year":"2019","unstructured":"McGarry A, McDermott MP, Kieburtz K, Fung WLA, McCusker E, Peng J, de Blieck EA, Cudkowicz M (2019) Risk factors for suicidality in Huntington disease: an analysis of the 2CARE clinical trial. Neurology 92:e1643\u2013e1651","journal-title":"Neurology"},{"key":"2750_CR65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1212\/CPJ.0000000000001161","volume":"12","author":"A McGarry","year":"2022","unstructured":"McGarry A, Auinger P, Kieburtz KD, Bredlau AL, Hersch SM, Rosas HD (2022) Suicidality risk factors across the CARE-HD, 2CARE, and CREST-E clinical trials in Huntington disease. Neurol Clin Pract 12:131\u2013138","journal-title":"Neurol Clin Pract"},{"key":"2750_CR66","doi-asserted-by":"publisher","first-page":"fcac278","DOI":"10.1093\/braincomms\/fcac278","volume":"4","author":"DJ McLauchlan","year":"2022","unstructured":"McLauchlan DJ, Lancaster T, Craufurd D, Linden DEJ, Rosser AE (2022) Different depression: motivational anhedonia governs antidepressant efficacy in Huntington\u2019s disease. Brain Commun 4:fcac278","journal-title":"Brain Commun"},{"key":"2750_CR67","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1111\/bph.12783","volume":"171","author":"CE McOmish","year":"2014","unstructured":"McOmish CE, Burrows EL, Hannan AJ (2014) Identifying novel interventional strategies for psychiatric disorders: integrating genomics, \u201cenviromics\u201d and gene-environment interactions in valid preclinical models. Br J Pharmacol 171:4719\u20134728","journal-title":"Br J Pharmacol"},{"key":"2750_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.825532","volume":"12","author":"MJ Molnar","year":"2022","unstructured":"Molnar MJ, Molnar V, Fedor M, Csehi R, Acsai K, Borsos B, Grosz Z (2022) Improving mood and cognitive symptoms in Huntington\u2019s disease with cariprazine treatment. Front Psychiatry 12:825532","journal-title":"Front Psychiatry"},{"key":"2750_CR69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1192\/bjb.2020.51","volume":"45","author":"W Mowafi","year":"2021","unstructured":"Mowafi W, Millard J (2021) Electroconvulsive therapy for severe depression, psychosis and chorea in a patient with Huntington\u2019s disease: case report and review of the literature. Bjpsych Bull 45:97\u2013104","journal-title":"Bjpsych Bull"},{"key":"2750_CR70","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuroscience.2012.05.043","volume":"251","author":"J Nithianantharajah","year":"2013","unstructured":"Nithianantharajah J, Hannan AJ (2013) Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington\u2019s disease. Neuroscience 251:66\u201374","journal-title":"Neuroscience"},{"key":"2750_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2022.111023","volume":"162","author":"AC Ogilvie","year":"2022","unstructured":"Ogilvie AC, Carnahan RM, Chrischilles EA, Schultz JL (2022) The effects of antidepressants on depressive symptoms in manifest Huntington\u2019s disease. J Psychosom Res 162:111023","journal-title":"J Psychosom Res"},{"key":"2750_CR72","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/hmg\/ddn385","volume":"18","author":"TY Pang","year":"2009","unstructured":"Pang TY, Du X, Zajac MS, Howard ML, Hannan AJ (2009) Altered serotonin receptor expression is associated with depression-related behavior in the R6\/1 transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet 18:753\u2013766","journal-title":"Hum Mol Genet"},{"key":"2750_CR73","first-page":"216","volume":"15","author":"T Patzold","year":"2002","unstructured":"Patzold T, Br\u00fcne M (2002) Obsessive compulsive disorder in Huntington disease: a case of isolated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol Behav Neurol 15:216\u2013219","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"2750_CR74","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1176\/jnp.17.4.496","volume":"17","author":"JS Paulsen","year":"2005","unstructured":"Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, McDowell B, Turner B (2005) Depression and stages of Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 17:496\u2013502","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2750_CR75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/B978-0-12-801893-4.00006-7","volume":"144","author":"JS Paulsen","year":"2017","unstructured":"Paulsen JS, Miller AC, Hayes T, Shaw E (2017) Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol 144:69\u201391","journal-title":"Handb Clin Neurol"},{"key":"2750_CR76","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1176\/appi.ajp.2009.09070973","volume":"167","author":"RH Perlis","year":"2010","unstructured":"Perlis RH, Smoller JW, Mysore J, Sun M, Gillis T, Purcell S, Rietschel M, N\u00f6then MM, Witt S, Maier W, Iosifescu DV, Sullivan P, Rush AJ, Fava M, Breiter H, Macdonald M, Gusella J (2010) Prevalence of incompletely penetrant Huntington\u2019s disease alleles among individuals with major depressive disorder. Am J Psychiatry 167:574\u2013579","journal-title":"Am J Psychiatry"},{"key":"2750_CR77","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF03160062","volume":"12","author":"CE Peyser","year":"1990","unstructured":"Peyser CE, Folstein SE (1990) Huntington\u2019s disease as a model for mood disorders. Clues from neuropathology and neurochemistry. Mol Chem Neuropathol 12:99\u2013119","journal-title":"Mol Chem Neuropathol"},{"key":"2750_CR78","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1212\/WNL.0000000000002001","volume":"85","author":"K Pigott","year":"2015","unstructured":"Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D (2015) Longitudinal study of normal cognition in Parkinson disease. Neurology 85:1276\u20131282","journal-title":"Neurology"},{"key":"2750_CR79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fnbeh.2014.00135","volume":"8","author":"P Pla","year":"2014","unstructured":"Pla P, Orvoen S, Saudou F, David DJ, Humbert S (2014) Mood disorders in Huntington\u2019s disease: from behavior to cellular and molecular mechanisms. Front Behav Neurosci 8:135","journal-title":"Front Behav Neurosci"},{"key":"2750_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","volume":"32","author":"SH Preskorn","year":"1997","unstructured":"Preskorn SH (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32:1\u201321","journal-title":"Clin Pharmacokinet"},{"key":"2750_CR81","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1176\/jnp.8.3.338","volume":"8","author":"NG Ranen","year":"1996","unstructured":"Ranen NG, Lipsey JR, Treisman G, Ross CA (1996) Sertraline in the treatment of severe aggressiveness in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 8:338\u2013340","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2750_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022133","volume":"6","author":"T Renoir","year":"2011","unstructured":"Renoir T, Zajac MS, Du X, Pang TY, Leang L, Chevarin C, Lanfumey L, Hannan AJ (2011) Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington\u2019s disease and depression. PLoS ONE 6:e22133","journal-title":"PLoS ONE"},{"key":"2750_CR83","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/JHD-120039","volume":"1","author":"T Renoir","year":"2012","unstructured":"Renoir T, Argyropoulos A, Hannan AJ (2012a) Antidepressant-like effect of the norepinephrine-dopamine reuptake inhibitor bupropion in a mouse model of Huntington\u2019s disease with dopaminergic dysfunction. J Huntingtons Dis 1:261\u2013266","journal-title":"J Huntingtons Dis"},{"key":"2750_CR84","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1476-5381.2011.01567.x","volume":"165","author":"T Renoir","year":"2012","unstructured":"Renoir T, Pang TY, Zajac MS, Chan G, Du X, Leang L, Chevarin C, Lanfumey L, Hannan AJ (2012b) Treatment of depressive-like behaviour in Huntington\u2019s disease mice by chronic sertraline and exercise. Br J Pharmacol 165:1375\u20131389","journal-title":"Br J Pharmacol"},{"key":"2750_CR85","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/WNN.0000000000000301","volume":"35","author":"NP Rocha","year":"2022","unstructured":"Rocha NP, Tuazon MR, Patino J, Furr Stimming E, Teixeira AL (2022) Clinical correlates of depression and suicidality in Huntington disease: an analysis of the enroll-hd observational study. Cogn Behav Neurol 35:85\u201394","journal-title":"Cogn Behav Neurol"},{"key":"2750_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.11.020","volume":"106","author":"J Ruiz-Idiago","year":"2023","unstructured":"Ruiz-Idiago J, Pomarol-Clotet E, Salvador R (2023) Longitudinal analysis of neuropsychiatric symptoms in a large cohort of early-moderate manifest Huntington\u2019s disease patients. Parkinsonism Relat Disord 106:105228","journal-title":"Parkinsonism Relat Disord"},{"key":"2750_CR87","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","volume":"91","author":"JL Schultz","year":"2018","unstructured":"Schultz JL, Killoran A, Nopoulos PC, Chabal CC, Moser DJ, Kamholz JA (2018) Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology 91:e202\u2013e207","journal-title":"Neurology"},{"key":"2750_CR88","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1176\/appi.neuropsych.18120319","volume":"32","author":"J Sellers","year":"2020","unstructured":"Sellers J, Ridner SH, Claassen DO (2020) A systematic review of neuropsychiatric symptoms and functional capacity in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 32:109\u2013124","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2750_CR89","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.psyneuen.2012.10.020","volume":"38","author":"CA Shirbin","year":"2013","unstructured":"Shirbin CA, Chua P, Churchyard A, Lowndes G, Hannan AJ, Pang TY, Chiu E, Stout JC (2013) Cortisol and depression in pre-diagnosed and early stage Huntington\u2019s disease. Psychoneuroendocrinology 38:2439\u20132447","journal-title":"Psychoneuroendocrinology"},{"key":"2750_CR90","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-0447.1994.tb01587.x","volume":"90","author":"R Shiwach","year":"1994","unstructured":"Shiwach R (1994) Psychopathology in Huntington\u2019s disease patients. Acta Psychiatr Scand 90:241\u2013246","journal-title":"Acta Psychiatr Scand"},{"key":"2750_CR91","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1017\/S109285290002201X","volume":"6","author":"JR Slaughter","year":"2001","unstructured":"Slaughter JR, Martens MP, Slaughter KA (2001) Depression and Huntington\u2019s disease: prevalence, clinical manifestations, etiology, and treatment. CNS Spectr 6:306\u2013326","journal-title":"CNS Spectr"},{"key":"2750_CR92","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1037\/a0029218","volume":"26","author":"MM Smith","year":"2012","unstructured":"Smith MM, Mills JA, Epping EA, Westervelt HJ, Paulsen JS (2012) Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. Neuropsychology 26:664\u2013669","journal-title":"Neuropsychology"},{"key":"2750_CR93","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1017\/S003329171300247X","volume":"44","author":"R Sprengelmeyer","year":"2014","unstructured":"Sprengelmeyer R, Orth M, M\u00fcller HP, Wolf RC, Gr\u00f6n G, Depping MS, Kassubek J, Justo D, Rees EM, Haider S, Cole JH, Hobbs NZ, Roos RA, D\u00fcrr A, Tabrizi SJ, S\u00fcssmuth SD, Landwehrmeyer GB (2014) The neuroanatomy of subthreshold depressive symptoms in Huntington\u2019s disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study. Psychol Med 44:1867\u20131878","journal-title":"Psychol Med"},{"key":"2750_CR94","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.3390\/cells11213381","volume":"11","author":"Y Sun","year":"2022","unstructured":"Sun Y, Tong H, Yang T, Liu L, Li XJ, Li S (2022) Insights into white matter defect in Huntington\u2019s disease. Cells 11:3381","journal-title":"Cells"},{"key":"2750_CR95","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cellsig.2004.12.007","volume":"17","author":"C Taylor","year":"2005","unstructured":"Taylor C, Fricker AD, Devi LA, Gomes I (2005) Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal 17:549\u2013557","journal-title":"Cell Signal"},{"key":"2750_CR96","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pscychresns.2012.01.002","volume":"203","author":"PG Unschuld","year":"2012","unstructured":"Unschuld PG, Joel SE, Pekar JJ, Reading SA, Oishi K, McEntee J, Shanahan M, Bakker A, Margolis RL, Bassett SS, Rosenblatt A, Mori S, van Zijl PC, Ross CA, Redgrave GW (2012) Depressive symptoms in prodromal Huntington\u2019s disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex. Psychiatry Res 203:166\u2013174","journal-title":"Psychiatry Res"},{"key":"2750_CR97","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.4088\/JCP.v69n1116","volume":"69","author":"E van Duijn","year":"2008","unstructured":"van Duijn E, Kingma EM, Timman R, Zitman FG, Tibben A, Roos RA, van der Mast RC (2008) Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington\u2019s disease compared with mutation-negative first-degree relatives. J Clin Psychiatry 69:1804\u20131810","journal-title":"J Clin Psychiatry"},{"key":"2750_CR98","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","volume":"85","author":"E van Duijn","year":"2014","unstructured":"van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, Anderson KE, van Walsem MR, van der Mast RC, Orth M, Landwehrmeyer GB (2014a) Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 85:1411\u20131418","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2750_CR99","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000343210","volume":"13","author":"E van Duijn","year":"2014","unstructured":"van Duijn E, Reedeker N, Giltay EJ, Eindhoven D, Roos RA, van der Mast RC (2014b) Course of irritability, depression and apathy in Huntington\u2019s disease in relation to motor symptoms during a two-year follow-up period. Neurodegener Dis 13:9\u201316","journal-title":"Neurodegener Dis"},{"key":"2750_CR100","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.969","volume":"7","author":"E van Duijn","year":"2021","unstructured":"van Duijn E, Fernandes AR, Abreu D, Ware JJ, Neacy E, Sampaio C (2021) Incidence of completed suicide and suicide attempts in a global prospective study of Huntington\u2019s disease. Bjpsych Open 7:e158","journal-title":"Bjpsych Open"},{"key":"2750_CR101","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol 44:559\u2013577","journal-title":"J Neuropathol Exp Neurol"},{"key":"2750_CR102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3233\/JHD-180299","volume":"7","author":"M Wesson","year":"2018","unstructured":"Wesson M, Boileau NR, Perlmutter JS, Paulsen JS, Barton SK, McCormack MK, Carlozzi NE (2018) Suicidal ideation assessment in individuals with premanifest and manifest Huntington disease. J Huntingtons Dis 7:239\u2013249","journal-title":"J Huntingtons Dis"},{"key":"2750_CR103","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00702-020-02187-x","volume":"127","author":"G Witkowski","year":"2020","unstructured":"Witkowski G, Jachinska K, Stepniak I, Ziora-Jakutowicz K, Sienkiewicz-Jarosz H (2020) Alterations in transcranial sonography among Huntington\u2019s disease patients with psychiatric symptoms. J Neural Transm (vienna) 127:1047\u20131055","journal-title":"J Neural Transm (vienna)"},{"key":"2750_CR104","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/hmg\/ddw077","volume":"25","author":"DJ Wright","year":"2016","unstructured":"Wright DJ, Gray LJ, Finkelstein DI, Crouch PJ, Pow D, Pang TY, Li S, Smith ZM, Francis PS, Renoir T, Hannan AJ (2016) N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington\u2019s disease. Hum Mol Genet 25:2923\u20132933","journal-title":"Hum Mol Genet"},{"key":"2750_CR105","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-023-04061-0","author":"Q Zhan","year":"2023","unstructured":"Zhan Q, Kong F, Shao S, Zhang B, Huang S (2023) Pathogenesis of depression in Alzheimer\u2019s disease. Neurochem Res. https:\/\/doi.org\/10.1007\/s11064-023-04061-0","journal-title":"Neurochem Res"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02750-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-024-02750-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02750-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T16:03:03Z","timestamp":1732982583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-024-02750-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":105,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2750"],"URL":"https:\/\/doi.org\/10.1007\/s00702-024-02750-w","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}